Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Mifepristone daily · 1 trial · 1 indication
Measured with the monthly version of the CAPS-5 (Clinician Administered PTSD scale) in patients with treatment-resistant PTSD. Minimum and maximum score range from 0-80, with higher scores indicating greater PTSD symptom severity.
| Arm | Type | Description |
|---|---|---|
| Mifepristone | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Mifepristone 1200 mg daily | DRUG | Oral tablets |
| Placebo | DRUG | Oral tablet |
Inclusion Criteria: * Mastery of Dutch language * Age of ≥ 18 years of age and able to give written IC * Participant agrees to be randomized * DSM-5 diagnosis of PTSD, confirmed with clinical interview (CAPS-5) * Treatment-resistant PTSD * CAPS-5 score ≥ 30 * Nonresponse to two evidence-based ...
Mifepristone daily, also known as Mifepristone 1200 mg daily, is an investigational small molecule being studied for the treatment of treatment-resistant PTSD. It is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
Mifepristone daily targets the glucocorticoid receptor (GR). It is a GR antagonist, meaning it blocks the receptor's activity. This mechanism is being investigated in the context of treatment-resistant PTSD, as GR antagonism may help modulate stress-related pathways.
Mifepristone daily is being developed by Corcept Therapeutics Incorporated, a biopharmaceutical company. The company's stock ticker is CORT. The drug is currently in Phase 2 clinical trials for treatment-resistant PTSD.
Mifepristone daily is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by the FDA or other regulatory agencies. The ongoing Phase 2 trial is actively recruiting participants.
Mifepristone daily is being evaluated in one active Phase 2 clinical trial, NCT06689254, titled "REVERSE: Improving Treatment-resistant Post Traumatic Stress Disorder (PTSD) with Glucocorticoid Receptor (GR) Antagonism." This randomized, double-blind, placebo-controlled trial is recruiting 60 participants in the Netherlands.
Yes, Mifepristone daily is also known as Mifepristone 1200 mg daily. The two names refer to the same investigational drug being developed by Corcept Therapeutics for treatment-resistant PTSD.